![18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-17460-0/MediaObjects/41598_2022_17460_Fig1_HTML.png "18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports")
18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports
![Figure 2, [Patient selection for targeted radionuclide...]. - Prostate Cancer - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK571320/bin/chapter6_f2.jpg "Figure 2, [Patient selection for targeted radionuclide...]. - Prostate Cancer - NCBI Bookshelf")
Figure 2, [Patient selection for targeted radionuclide...]. - Prostate Cancer - NCBI Bookshelf
Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
Brazilian Journal Of Oncology - Metastatic castration-resistant prostate cancer (mCRPC) treated with 225Ac-PSMA-617. Case report
225Ac-PSMA-617 for Therapy of Prostate Cancer - ScienceDirect
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F1.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
A) 68 Ga-PSMA-11 PET/CT scan of patient with pretherapeutic tumor... | Download Scientific Diagram
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation
Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. | Semantic Scholar
Synthesis of 225Ac-PSMA-617 for Preclinical Use | Bentham Science
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study | European Journal of Nuclear Medicine and Molecular Imaging
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA - European Urology
Lu-177 PSMA therapy vs Ac-225 PSMA therapy
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
![Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/early/2023/08/23/jnumed.123.265546/F6.large.jpg "Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine")
Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA - European Urology
225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient - Omer Aras, Stefan Harmsen, Richard Ting, Haluk B Sayman, 2021
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy - ScienceDirect
Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher Wallis & Zachary Klaassen
Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.
ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225 | EJNMMI Research | Full Text
![Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00715/article_deploy/html/images/pharmaceutics-13-00715-g001.png "Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC")